150 related articles for article (PubMed ID: 38558905)
1. Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation.
Ido T; Sasaki S; Sotomi Y; Hirata A; Makino N; Hayashi T; Sakata Y; Hirayama A; Higuchi Y
Am Heart J Plus; 2022 Oct; 22():100203. PubMed ID: 38558905
[TBL] [Abstract][Full Text] [Related]
2. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC;
Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284
[TBL] [Abstract][Full Text] [Related]
3. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.
Clemens A; Noack H; Brueckmann M; Lip GY
PLoS One; 2014; 9(6):e99276. PubMed ID: 24911432
[TBL] [Abstract][Full Text] [Related]
4. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
5. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
6. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
8. Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.
Polymeris AA; Zietz A; Schaub F; Meya L; Traenka C; Thilemann S; Wagner B; Hert L; Altersberger VL; Seiffge DJ; Lyrer F; Dittrich T; Piot I; Kaufmann J; Barone L; Dahlheim L; Flammer S; Avramiotis NS; Peters N; De Marchis GM; Bonati LH; Gensicke H; Engelter ST; Lyrer PA
Eur Stroke J; 2022 Sep; 7(3):221-229. PubMed ID: 36082252
[TBL] [Abstract][Full Text] [Related]
9. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
Gedikli Ö; Altay S; Ünlü S; Çakmak HA; Aşkın L; Yanık A; Beşli F; Sinan ÜY; Canpolat U; Şahin M; Pehlivanoğlu S
Anatol J Cardiol; 2021 Mar; 25(3):196-204. PubMed ID: 33690135
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
[TBL] [Abstract][Full Text] [Related]
11. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.
Ageno W; Beyer-Westendorf J; Rubboli A
Expert Opin Pharmacother; 2017 Sep; 18(13):1325-1332. PubMed ID: 28786696
[TBL] [Abstract][Full Text] [Related]
12. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
McHorney CA; Peterson ED; Ashton V; Laliberté F; Crivera C; Germain G; Sheikh N; Schein J; Lefebvre P
Curr Med Res Opin; 2019 Apr; 35(4):653-660. PubMed ID: 30265159
[TBL] [Abstract][Full Text] [Related]
13. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
14. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
15. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW
J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
17. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
[TBL] [Abstract][Full Text] [Related]
18. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Rasmussen LH; Larsen TB; Graungaard T; Skjøth F; Lip GY
BMJ; 2012 Nov; 345():e7097. PubMed ID: 23129490
[TBL] [Abstract][Full Text] [Related]
19. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
